HighGravityDataEdwards Lifesciences — Apr 23, 2026 release
Fiscal 2026 first-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001099800-26-000021
Showing in the filing
Sales growth rate
“9% to 11%”
Period
FY2026
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 14
Constant currency sales growth for FY2026
“9% to 11%”
Gross margin for FY2026
“78% to 79%”
R&D expense as a percentage of sales for FY2026
“approximately 17%”
Operating profit margin for FY2026
“high end of the company’s original 28% to 3 29% guidance range”
Constant currency operating margin expansion for FY2026
“approximately 150 basis points”
Sales growth rate for FY2026
“9% to 11%”
TAVR product group sales growth rate for FY2026
“7% to 9%”
Total company sales for FY2026
“$6.5 to $6.9 billion”
TAVR sales for FY2026
“$4.7 to $5.0 billion”
TMTT sales for FY2026
“$740 to $780 million”
Surgical sales growth for FY2026
“mid-single-digit”
Adjusted EPS for FY2026
“$2.95 to $3.05”
Total sales for Q2 FY2026
“between $1.66 and $1.74 billion”
Adjusted EPS for Q2 FY2026
“$0.70 to $0.76”
Exhibit 99.1 · the passage around this item
… earlier in the release
Edwards has approximately $1.5 billion remaining under its share repurchase authorization. Outlook Due to stronger-than-expected first quarter results, Edwards is raising its full-year 2026 sales growth rate guidance to 9% to 11% from 8% to 10% and TAVR product group sales growth rate guidance to 7% to 9% from 6% to 8%. Edwards now expects total company sales of $6.5 to $6.9 billion, and TAVR sales of $4.7 to $5.0 billion at current exchange rates. The company continues to expect $740 to $780 million in TMTT sales and mid-single-digit sales growth in Surgical in 2026. In addition, Edwards is raising the midpoint of its full-year adjusted EPS guidance with a new range of $2.95 to $3.05 from $2.90 to $3.05. For the second quarter of 2026, the company projects total sales to be between $1.66 and $1.74 billion and adjusted EPS of $0.70 to $0.76. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube. Conference Call and Webcast Information The company will be hosting a confere
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.